# A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy

> **NCT06172634** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Soonchunhyang University Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Pancreas Cancer

## Interventions

- **DRUG:** dentritic cell infusion and immunecheckpoint inhibitor

## Key facts

- **NCT ID:** NCT06172634
- **Lead sponsor:** Soonchunhyang University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06172634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06172634, "A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06172634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*